Mannatech Dismisses Auditor BDO, Engages CBIZ Amid Going-Concern Doubt
MTEX has more than doubled off its 52-week low of $3.8 on elevated volume (2.9× avg).
Summary
Mannatech dismissed BDO as its auditor on October 15, 2026 and engaged CBIZ CPAs for fiscal 2026, starting with the Q3 review. The filing reports no disagreements or reportable events, but the change lands while the company is already flagged for going-concern doubt and a Nasdaq equity deficiency.
Key Events · Corporate Governance and Compliance · MTEX
-
Auditor Dismissed and Replaced
The Audit Committee dismissed BDO USA, P.C. effective October 15, 2026 and engaged CBIZ CPAs P.C. for the fiscal year ending December 31, 2026.
-
No Disagreements Disclosed
The filing states there were no disagreements or reportable events with BDO during fiscal 2024, fiscal 2025, or the interim period through October 15, 2026.
-
Going-Concern Warning in Prior Opinion
BDO's report for fiscal year 2025 contained an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
-
CBIZ Starts With Q3 Review
CBIZ's engagement begins with the review of condensed consolidated financial statements for the quarter ended September 30, 2026.
Analysis · MTEX · Life Sciences
The timing is what matters here: Mannatech swapped auditors six days ago. BDO's FY2025 opinion already carried a going-concern explanatory paragraph, and the company's Q2 10-Q (filed August 12) disclosed going-concern doubt plus a Nasdaq equity deficiency. Changing auditors while those conditions are live invites scrutiny of whether the departure was voluntary, even though the filing states there were no disagreements or reportable events. CBIZ takes over immediately, beginning with the September 30, 2026 quarterly review — so the new firm's first real test is the Q3 numbers. BDO's concurrence letter is still outstanding and will come by amendment.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.80%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTEX was trading at $8.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9M. The 52-week trading range was $3.80 to $12.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.